Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Jan 12, 2018 6:57pm
307 Views
Post# 27346675

RE:RE:RE:RE:RE:RE:Ryplazim Will Be Used To Treat Animals

RE:RE:RE:RE:RE:RE:Ryplazim Will Be Used To Treat AnimalsSorry to lift a leg and pee on the pet parade, but how many insurers or pet owners are going to line up for Ryzaplin at somewhere between $150-$200k ?

The other indications are SO massive its not going to matter.  If it works in Diabetic foot ulcer treatment or basic wound healing its blockbuster beyond any rationale expectations
Bullboard Posts